ClinicalTrials.gg
CompletedNCT03695237Updated May 29, 2024Results posted

A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

A Phase 3 interventional study of Leuprolide Acetate (LA) in Central Precocious Puberty (CPP), sponsored by AbbVie. Completed at 18 sites in 2 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2024-05-29.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing leuprolide in Puberty, Precocious — 2 open to participants now, 2 under way, 1 of them phase 3. Leuprolide · Puberty, Precocious.

Enrollment
11th of 14
45 · median 68
Started
2018
the only one that year
Phase 3
6 of 14
1 open now
Registered
10th of 14
by date
Lead sponsor
1 of 14
AbbVie

Among the 14 studies testing leuprolide in Puberty, Precocious, this one is the 11th largest by enrollment, is the only one that started in 2018, is one of 6 in phase 3, and was the 10th registered.

Puberty, Precocious

75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.

Browse Puberty, Precocious studies →

Open to participants now

2 of the 14 studies testing leuprolide in Puberty, Precocious are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 2 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing leuprolide in Puberty, Precocious, or all of them as a file.
02

Study summary

The primary objective of the study is to assess the safety and efficacy of a leuprolide acetate (LA) 45 mg 6-month depot formulation for the treatment of CPP in children who are either naïve to treatment with a gonadotropin-releasing hormone agonist (GnRHa) or who have been previously treated with a GnRHa.

03

Conditions studied

  • Central Precocious Puberty (CPP)

Browse trials for

Keywords

  • Central Precocious Puberty (CPP)
  • Leuprolide Acetate (LA)
04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Children with CPP who are naïve to treatment with a gonadotropin-releasing hormone agonist (GnRHa) (females 2 - 8 years of age, or males 2 - 9 years of age) or who have been on standard GnRHa therapy for at least 6 months (females 2 - 10 years of age, or males 2 - 11 years of age).
  • No history of medical conditions or any other reason that the investigator determines would make the participant an unsuitable candidate to receive study drug.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Leuprolide Acetate (LA)

    Participants received leuprolide acetate (LA) 45 mg every 6 months administered as an intramuscular injection for up to 144 weeks.

    Drug: Leuprolide Acetate (LA)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Suppression of Peak Gonadotropin-releasing Hormone Agonist (GnRHa)-Stimulated Luteinizing Hormone (LH) to Less Than 4 mlU/mL at Week 24

    Suppression of GnRHa-stimulated luteinizing hormone (LH) was measured using a peak GnRHa stimulation test, performed using subcutaneous injection with an aqueous formulation of leuprolide acetate at 20 µg/kg. Peak stimulated LH was calculated by taking the maximum LH concentrations measured from blood samples taken at 30 or 60 min following the GnRHa stimulation test. Suppression of GnRHa-stimulated luteinizing hormone is defined as peak stimulated LH less than 4 mIU/mL.

    Time frame: Week 24 (prior to the Week 24 dose); samples for LH measurement were taken 30 and 60 minutes after the stimulation test injection.

Secondary outcomes

  1. Part 1: Percentage of Participants With Suppression of Peak GnRHa-stimulated LH to Less Than 4 mlU/mL at Weeks 12, 20, 44, and 48

    Suppression of GnRHa-stimulated luteinizing hormone (LH) was measured using a peak GnRHa stimulation test, performed using subcutaneous injection with an aqueous formulation of leuprolide acetate at 20 µg/kg. Peak stimulated LH was calculated by taking the maximum LH concentrations measured from blood samples taken at 30 or 60 min following the GnRHa stimulation test. Suppression of GnRHa-stimulated luteinizing hormone is defined as peak stimulated LH less than 4 mIU/mL.

    Time frame: Weeks 12, 20, 44, and 48 (prior to Week 48 dose); samples for LH measurement were taken 30 and 60 minutes after the stimulation test injection.

  2. Part 1: Percentage of Female Participants With Suppression of Basal Estradiol to < 20 pg/mL at Weeks 12, 20, 24, 44, and 48

    Estradiol concentrations were measured from blood samples taken at each study visit prior to stimulation testing (and prior to study drug administration at Weeks 24 and 48).

    Time frame: Weeks 12, 20, 24, 44, and 48

  3. Part 1: Percentage of Male Participants With Suppression of Basal Testosterone to < 30 ng/dL at Weeks 12, 20, 24, 44, and 48

    Testosterone concentrations were measured from blood samples taken at each study visit prior to stimulation testing (and prior to study drug administration for Weeks 24 and 48).

    Time frame: Weeks 12, 20, 24, 44, and 48

  4. Parts 1 and 2: Percentage of Participants With Suppression of the Physical Signs of Puberty

    Breast development in females and testicular volume or genital development in males was assessed using modified Tanner staging, on a scale from Stage 1 (prepubertal) to Stage 5 (adult characteristics). Females: Suppression is defined as regression or no progression of breast development according to modified Tanner staging. Males: Suppression is defined as regression or no progression in testicular volume and genital staging according to modified Tanner staging.

    Time frame: Part 1: Weeks 24 and 48; Part 2: Weeks 72, 96, 120, and 144

  5. Parts 1 and 2: Change From Baseline in Incremental Growth Rate

    Growth rate (height in centimeter/year) was calculated both prior to treatment in the study and during the study. For Baseline calculation a historical measurement of height at least 6 months prior to Screening and the Screening value was used.

    Time frame: Part 1: Baseline and Weeks 4, 12, 20, 24, 44, and 48; Part 2: Weeks 72, 96, 120, and 144

  6. Parts 1 and 2: Ratio of Change From Baseline in Bone Age to Change From Baseline in Chronological Age

    Bone age was assessed from radiographs of the hand and wrist by a central imaging vendor using the BoneXpert automated system. A ratio less than 1 indicates less advancement of bone age compared to chronological age.

    Time frame: Part 1: Baseline and Weeks 24 and 48; Part 2: Weeks 72, 96, 120, and 144

  7. Part 2: Percentage of Participants With Maintenance of Suppression of GnRHa-stimulated LH (< 4 mlU/mL)

    Suppression of GnRHa-stimulated luteinizing hormone (LH) was measured using a peak GnRHa stimulation test, performed using subcutaneous injection with an aqueous formulation of leuprolide acetate at 20 µg/kg. Peak stimulated LH was calculated by taking the maximum LH concentrations measured from blood samples taken at 30 or 60 min following the GnRHa stimulation test. Suppression of GnRHa-stimulated luteinizing hormone is defined as peak stimulated LH less than 4 mIU/mL.

    Time frame: Weeks 72, 96, 120, and 144

  8. Part 2: Percentage of Female Participants With Maintenance of Suppression of Basal Estradiol to < 20 pg/mL

    Estradiol concentrations were measured from blood samples taken at each study visit prior to stimulation testing.

    Time frame: Weeks 72, 96, 120, and 144

  9. Part 2: Percentage of Male Participants With Maintenance of Suppression of Basal Testosterone to < 30 ng/dL

    Male participants with maintenance of suppression of testosterone to \< 30 ng/dL are assessed

    Time frame: Weeks 72, 96, 120, and 144

07

Results

Posted May 16, 2023

Participant flow

Participants were enrolled at 16 sites in the United States including Puerto Rico. The study enrolled pediatric participants with central precocious puberty (CPP) who were either naïve to treatment with a gonadotropin-releasing hormone receptor agonist (GnRHa) or who had been previously treated with a GnRHa.

Participant flow — Overall Study
MilestoneLeuprolide Acetate - Previously TreatedLeuprolide Acetate - Treament Naïve
Started1827
Completed820
Not completed107
Withdrew: Withdrawal by subject13
Withdrew: Lost to follow-up12
Withdrew: Other, not specified82

Outcome measures

PrimaryPercentage of Participants With Suppression of Peak Gonadotropin-releasing Hormone Agonist (GnRHa)-Stimulated Luteinizing Hormone (LH) to Less Than 4 mlU/mL at Week 24

Suppression of GnRHa-stimulated luteinizing hormone (LH) was measured using a peak GnRHa stimulation test, performed using subcutaneous injection with an aqueous formulation of leuprolide acetate at 20 µg/kg. Peak stimulated LH was calculated by taking the maximum LH concentrations measured from blood samples taken at 30 or 60 min following the GnRHa stimulation test. Suppression of GnRHa-stimulated luteinizing hormone is defined as peak stimulated LH less than 4 mIU/mL.

Time frame:
Week 24 (prior to the Week 24 dose); samples for LH measurement were taken 30 and 60 minutes after the stimulation test injection.
Reported as:
Number · percentage of participants
Percentage of Participants With Suppression of Peak Gonadotropin-releasing Hormone Agonist (GnRHa)-Stimulated Luteinizing Hormone (LH) to Less Than 4 mlU/mL at Week 24
percentage of participantsLeuprolide Acetate - Previously TreatedLeuprolide Acetate - Treament NaïveLeuprolide Acetate - Overall
Percentage of Participants With Suppression of Peak Gonadotropin-releasing Hormone Agonist (GnRHa)-Stimulated Luteinizing Hormone (LH) to Less Than 4 mlU/mL at Week 2494.4 (72.7 to 99.9)81.5 (61.9 to 93.7)86.7 (73.2 to 95.0)
SecondaryPart 1: Percentage of Participants With Suppression of Peak GnRHa-stimulated LH to Less Than 4 mlU/mL at Weeks 12, 20, 44, and 48

Suppression of GnRHa-stimulated luteinizing hormone (LH) was measured using a peak GnRHa stimulation test, performed using subcutaneous injection with an aqueous formulation of leuprolide acetate at 20 µg/kg. Peak stimulated LH was calculated by taking the maximum LH concentrations measured from blood samples taken at 30 or 60 min following the GnRHa stimulation test. Suppression of GnRHa-stimulated luteinizing hormone is defined as peak stimulated LH less than 4 mIU/mL.

Time frame:
Weeks 12, 20, 44, and 48 (prior to Week 48 dose); samples for LH measurement were taken 30 and 60 minutes after the stimulation test injection.
Reported as:
Number · percentage of participants
Part 1: Percentage of Participants With Suppression of Peak GnRHa-stimulated LH to Less Than 4 mlU/mL at Weeks 12, 20, 44, and 48
percentage of participantsLeuprolide Acetate - Previously TreatedLeuprolide Acetate - Treament NaïveLeuprolide Acetate - Overall
Week 1283.3 (58.6 to 96.4)88.9 (70.8 to 97.7)86.7 (73.2 to 95.0)
Week 2094.4 (72.7 to 99.9)85.2 (66.3 to 95.8)88.9 (76.0 to 96.3)
Week 4488.9 (65.3 to 98.6)88.9 (70.8 to 97.7)88.9 (76.0 to 96.3)
Week 4883.3 (58.6 to 96.4)92.6 (75.7 to 99.1)88.9 (76.0 to 96.3)
SecondaryPart 1: Percentage of Female Participants With Suppression of Basal Estradiol to < 20 pg/mL at Weeks 12, 20, 24, 44, and 48

Estradiol concentrations were measured from blood samples taken at each study visit prior to stimulation testing (and prior to study drug administration at Weeks 24 and 48).

Time frame:
Weeks 12, 20, 24, 44, and 48
Reported as:
Number · percentage of participants
Part 1: Percentage of Female Participants With Suppression of Basal Estradiol to < 20 pg/mL at Weeks 12, 20, 24, 44, and 48
percentage of participantsLeuprolide Acetate - Previously TreatedLeuprolide Acetate - Treament NaïveLeuprolide Acetate - Overall
Week 12100.0 (79.4 to 100.0)95.5 (77.2 to 99.9)97.4 (86.2 to 99.9)
Week 20100.0 (79.4 to 100.0)95.7 (78.1 to 99.9)97.4 (86.5 to 99.9)
Week 24100.0 (80.5 to 100.0)95.2 (76.2 to 99.9)97.4 (86.2 to 99.9)
Week 44100.0 (80.5 to 100.0)100.0 (85.2 to 100.0)100.0 (91.2 to 100.0)
Week 48100.0 (79.4 to 100.0)100.0 (85.8 to 100.0)100.0 (91.2 to 100.0)
SecondaryPart 1: Percentage of Male Participants With Suppression of Basal Testosterone to < 30 ng/dL at Weeks 12, 20, 24, 44, and 48

Testosterone concentrations were measured from blood samples taken at each study visit prior to stimulation testing (and prior to study drug administration for Weeks 24 and 48).

Time frame:
Weeks 12, 20, 24, 44, and 48
Reported as:
Number · percentage of participants
Part 1: Percentage of Male Participants With Suppression of Basal Testosterone to < 30 ng/dL at Weeks 12, 20, 24, 44, and 48
percentage of participantsLeuprolide Acetate - Previously TreatedLeuprolide Acetate - Treament NaïveLeuprolide Acetate - Overall
Week 12100.0 (2.5 to 100.0)100.0 (15.8 to 100.0)100.0 (29.2 to 100.0)
Week 20100.0 (2.5 to 100.0)100.0 (15.8 to 100.0)100.0 (29.2 to 100.0)
Week 24100.0 (2.5 to 100.0)100.0 (29.2 to 100.0)100.0 (39.8 to 100.0)
Week 44100.0 (2.5 to 100.0)100.0 (29.2 to 100.0)100.0 (39.8 to 100.0)
Week 48100.0 (2.5 to 100.0)100.0 (29.2 to 100.0)100.0 (39.8 to 100.0)
SecondaryParts 1 and 2: Percentage of Participants With Suppression of the Physical Signs of Puberty

Breast development in females and testicular volume or genital development in males was assessed using modified Tanner staging, on a scale from Stage 1 (prepubertal) to Stage 5 (adult characteristics). Females: Suppression is defined as regression or no progression of breast development according to modified Tanner staging. Males: Suppression is defined as regression or no progression in testicular volume and genital staging according to modified Tanner staging.

Time frame:
Part 1: Weeks 24 and 48; Part 2: Weeks 72, 96, 120, and 144
Reported as:
Number · percentage of participants
Parts 1 and 2: Percentage of Participants With Suppression of the Physical Signs of Puberty
percentage of participantsLeuprolide Acetate - Previously TreatedLeuprolide Acetate - Treament NaïveLeuprolide Acetate - Overall
Females: Week 2494.191.792.7
Females: Week 4888.291.790.2
Females: Week 7293.895.794.9
Females: Week 9610090.594.3
Females: Week 12091.789.590.3
Females: Week 14483.387.586.4
Males: Week 24066.750.0
Males: Week 4810066.775.0
Males: Week 72066.750.0
Males: Week 9610066.775.0
Males: Week 120066.750.0
Males: Week 144010050.0
SecondaryParts 1 and 2: Change From Baseline in Incremental Growth Rate

Growth rate (height in centimeter/year) was calculated both prior to treatment in the study and during the study. For Baseline calculation a historical measurement of height at least 6 months prior to Screening and the Screening value was used.

Time frame:
Part 1: Baseline and Weeks 4, 12, 20, 24, 44, and 48; Part 2: Weeks 72, 96, 120, and 144
Reported as:
Mean · cm/year
Parts 1 and 2: Change From Baseline in Incremental Growth Rate
cm/yearLeuprolide Acetate - Previously TreatedLeuprolide Acetate - Treament NaïveLeuprolide Acetate - Overall
Week 4-0.6 ± 9.99-0.9 ± 10.52-0.8 ± 10.19
Week 12-0.6 ± 4.09-2.9 ± 5.42-2.0 ± 5.02
Week 20-0.5 ± 2.61-3.8 ± 4.69-2.5 ± 4.28
Week 24-0.5 ± 2.81-3.7 ± 4.28-2.4 ± 4.03
Week 44-0.4 ± 2.48-4.1 ± 3.77-2.6 ± 3.76
Week 48-0.3 ± 2.67-3.5 ± 4.71-2.3 ± 4.32
Week 72-0.5 ± 2.09-4.3 ± 3.53-2.8 ± 3.55
Week 96-0.6 ± 2.29-4.9 ± 3.43-3.2 ± 3.68
Week 120-1.2 ± 1.96-5.6 ± 3.27-3.9 ± 3.54
Week 144-1.0 ± 1.63-5.3 ± 2.76-4.0 ± 3.19
SecondaryParts 1 and 2: Ratio of Change From Baseline in Bone Age to Change From Baseline in Chronological Age

Bone age was assessed from radiographs of the hand and wrist by a central imaging vendor using the BoneXpert automated system. A ratio less than 1 indicates less advancement of bone age compared to chronological age.

Time frame:
Part 1: Baseline and Weeks 24 and 48; Part 2: Weeks 72, 96, 120, and 144
Reported as:
Mean · ratio
Parts 1 and 2: Ratio of Change From Baseline in Bone Age to Change From Baseline in Chronological Age
ratioLeuprolide Acetate - Previously TreatedLeuprolide Acetate - Treament NaïveLeuprolide Acetate - Overall
Week 240.5 ± 0.800.7 ± 0.560.6 ± 0.66
Week 480.2 ± 1.360.6 ± 0.410.5 ± 0.93
Week 720.6 ± 0.310.6 ± 0.380.6 ± 0.35
Week 960.6 ± 0.320.7 ± 0.280.6 ± 0.29
Week 1200.5 ± 0.280.6 ± 0.340.6 ± 0.32
Week 1440.6 ± 0.260.6 ± 0.240.6 ± 0.24
SecondaryPart 2: Percentage of Participants With Maintenance of Suppression of GnRHa-stimulated LH (< 4 mlU/mL)

Suppression of GnRHa-stimulated luteinizing hormone (LH) was measured using a peak GnRHa stimulation test, performed using subcutaneous injection with an aqueous formulation of leuprolide acetate at 20 µg/kg. Peak stimulated LH was calculated by taking the maximum LH concentrations measured from blood samples taken at 30 or 60 min following the GnRHa stimulation test. Suppression of GnRHa-stimulated luteinizing hormone is defined as peak stimulated LH less than 4 mIU/mL.

Time frame:
Weeks 72, 96, 120, and 144
Reported as:
Number · percentage of participants
Part 2: Percentage of Participants With Maintenance of Suppression of GnRHa-stimulated LH (< 4 mlU/mL)
percentage of participantsLeuprolide Acetate - Previously TreatedLeuprolide Acetate - Treament NaïveLeuprolide Acetate - Overall
Week 7288.2 (63.6 to 98.5)96.2 (80.4 to 99.9)93.0 (80.9 to 98.5)
Week 9693.3 (68.1 to 99.8)95.7 (78.1 to 99.9)94.7 (82.3 to 99.4)
Week 120100.0 (75.3 to 100.0)100.0 (84.6 to 100.0)100.0 (90.0 to 100.0)
Week 144100.0 (59.0 to 100.0)100.0 (79.4 to 100.0)100.0 (85.2 to 100.0)
SecondaryPart 2: Percentage of Female Participants With Maintenance of Suppression of Basal Estradiol to < 20 pg/mL

Estradiol concentrations were measured from blood samples taken at each study visit prior to stimulation testing.

Time frame:
Weeks 72, 96, 120, and 144
Reported as:
Number · percentage of participants
Part 2: Percentage of Female Participants With Maintenance of Suppression of Basal Estradiol to < 20 pg/mL
percentage of participantsLeuprolide Acetate - Previously TreatedLeuprolide Acetate - Treament NaïveLeuprolide Acetate - Overall
Week 72100.0 (79.4 to 100.0)100.0 (85.2 to 100.0)100.0 (91.0 to 100.0)
Week 96100.0 (76.8 to 100.0)100.0 (83.2 to 100.0)100.0 (89.7 to 100.0)
Week 120100.0 (71.5 to 100.0)100.0 (82.4 to 100.0)100.0 (88.4 to 100.0)
Week 144100.0 (54.1 to 100.0)100.0 (78.2 to 100.0)100.0 (83.9 to 100.0)
SecondaryPart 2: Percentage of Male Participants With Maintenance of Suppression of Basal Testosterone to < 30 ng/dL

Male participants with maintenance of suppression of testosterone to \< 30 ng/dL are assessed

Time frame:
Weeks 72, 96, 120, and 144
Reported as:
Number · percentage of participants
Part 2: Percentage of Male Participants With Maintenance of Suppression of Basal Testosterone to < 30 ng/dL
percentage of participantsLeuprolide Acetate - Previously TreatedLeuprolide Acetate - Treament NaïveLeuprolide Acetate - Overall
Week 72100.0 (2.5 to 100.0)100.0 (29.2 to 100.0)100.0 (39.8 to 100.0)
Week 96100.0 (2.5 to 100.0)100.0 (29.2 to 100.0)100.0 (39.8 to 100.0)
Week 120100.0 (2.5 to 100.0)100.0 (29.2 to 100.0)100.0 (39.8 to 100.0)
Week 144100.0 (2.5 to 100.0)100.0 (2.5 to 100.0)100.0 (15.8 to 100.0)

Adverse events

Collected over From screening through end of study; median 949.5 and 1092.0 days for previously-treated and treatment-naïve participants, respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Leuprolide Acetate - Previously Treated0/18 (0%)0/18 (0%)18/18 (100%)
Leuprolide Acetate - Treament Naïve0/27 (0%)1/27 (3.7%)27/27 (100%)
Most frequent serious events
Most frequent serious events
EventLeuprolide Acetate - Previously TreatedLeuprolide Acetate - Treament Naïve
AFFECTIVE DISORDERPsychiatric disorders0/181/27
Most frequent other events
Showing 10 of 112
Most frequent other events
EventLeuprolide Acetate - Previously TreatedLeuprolide Acetate - Treament Naïve
INJECTION SITE PAINGeneral disorders16/1826/27
HEADACHENervous system disorders9/189/27
INJECTION SITE REACTIONGeneral disorders4/189/27
PYREXIAGeneral disorders6/185/27
COVID-19Infections and infestations3/189/27
PAINGeneral disorders5/185/27
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations5/187/27
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders5/183/27
ABDOMINAL PAIN UPPERGastrointestinal disorders1/186/27
INFLUENZAInfections and infestations4/183/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)Leuprolide Acetate - Previously TreatedLeuprolide Acetate - Treament NaïveTotal
Mean8.1 ± 1.737.7 ± 0.837.8 ± 1.27
Sex: Female, Male
Sex: Female, Male(Participants)Leuprolide Acetate - Previously TreatedLeuprolide Acetate - Treament NaïveTotal
Female172441
Male134
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Leuprolide Acetate - Previously TreatedLeuprolide Acetate - Treament NaïveTotal
Hispanic or Latino2911
Not Hispanic or Latino161834
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Leuprolide Acetate - Previously TreatedLeuprolide Acetate - Treament NaïveTotal
American Indian or Alaska Native101
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American437
White121830
More than one race066
Unknown or Not Reported000
Age at onset of CPP
Age at onset of CPP(years)Leuprolide Acetate - Previously TreatedLeuprolide Acetate - Treament NaïveTotal
Females5.9 ± 2.376.7 ± 0.996.4 ± 1.74
Males2.16.9 ± 2.585.7 ± 3.19
Overall5.7 ± 2.466.8 ± 1.186.3 ± 1.86
08

Study locations

18 sites
  • Pediatric Endocrinology Associates /ID# 200629
    Long Beach, California 90806-1651, United States
  • Rady Children's Hospital San Diego /ID# 202491
    San Diego, California 92123, United States
  • Children's Hospital Colorado /ID# 201645
    Aurora, Colorado 80045, United States
  • Pediatric Endocrine Associates /ID# 201089
    Greenwood Village, Colorado 80111, United States
  • Nemours Children's Health System /ID# 201331
    Jacksonville, Florida 32207, United States
  • Arnold Palmer Hospital /ID# 201624
    Orlando, Florida 32806, United States
  • Van Meter Pediatric Endocrinology /ID# 201688
    Atlanta, Georgia 30318-2508, United States
  • Rocky Mountain Diabetes and Osteoporosis Center /ID# 209878
    Idaho Falls, Idaho 83404-7596, United States
  • Indiana University /ID# 200526
    Indianapolis, Indiana 46202, United States
  • Pediatric Endocrine Associates /ID# 202396
    Boston, Massachusetts 02114, United States
  • University of Minnesota /ID# 200508
    Minneapolis, Minnesota 55455-1450, United States
  • Children's Mercy Hospital/ID# 200221
    Kansas City, Missouri 64111, United States
  • University of Oklahoma /ID# 200659
    Tulsa, Oklahoma 74135-2527, United States
  • Penn State Hershey Medical Ctr /ID# 200287
    Hershey, Pennsylvania 17033-2360, United States
  • Children's Hospital of Philadelphia - Main /ID# 203846
    Philadelphia, Pennsylvania 19104-4319, United States
  • Cook Children's Med. Center /ID# 212937
    Fort Worth, Texas 76104, United States
  • Multicare Institute for Research and Innovation /ID# 202188
    Tacoma, Washington 98405, United States
  • Pediatric Endocrine Research Associates /ID# 200131
    San Juan, 00935, Puerto Rico
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in May 2021, 30 months.

Results were first posted in May 2023, 2 years after primary completion. A results delay was requested in May 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2018
First posted
Oct 4, 2018
StartActual
Oct 24, 2018
Primary completionActual
May 6, 2021
CompletionActual
Nov 29, 2023
Results delay requested
May 25, 2021
Results first posted
May 16, 2023
Last update
May 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03695237
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 4, 2018
Start date
Oct 24, 2018
Primary completion
May 6, 2021
Completion
Nov 29, 2023
Results posted
May 16, 2023
Last update
May 29, 2024

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion